The global immunoassay for neurological biomarkers market size is expected to reach USD 2.24 billion by 2030, registering a CAGR of 17.8% from 2023 to 2030. Usage of immunoassays for neurological biomarker testing is likely to witness significant growth during the forecast period owing to increasing prevalence of neurological diseases, growing awareness regarding biomarker usage, and extensive R&D activities as well as ongoing advancements to improve the sensitivity of kits & instruments to measure diagnostic biomarkers.
Biomarkers play a crucial role in selecting appropriate therapies and tracking disease progression. This can be evidenced by research initiatives and clinical studies that are being conducted in hospitals for developing biomarker tests, which, in turn, is anticipated to fuel market growth. For instance, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau is studying circulating microparticles to develop new biomarkers for neurological prognosis of patients.
Moreover, advancements in technologies help in the identification of early signs related to neurological disorders by detecting biomarkers in serum and blood. Some of the multiplexed immunoassay technologies include Olink's Proximity Extension Assay (PEA) and Quanterix's Simoa. Simoa is based on digitizing ELISA, which allows quantifying biomarkers in both blood and CSF, whereas PEA is based on nucleic acid technologies, helps prevent antibody cross-reactivity with immunoassay.
The rising number of disease-modifying therapies for neurological disorders is boosting the demand for immunoassays for biomarker testing in the market. For instance, in June 2021, the FDA granted accelerated approval to Aduhelm indicated for Alzheimer’s disease. Similarly, in January 2023, the FDA approved Alzheimer’s drug Leqembi (lecanemab). In addition, there are a number of disease-modifying therapies under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative growth opportunities for market players. For instance, as of November 2022, Roche’s RO7046015, indicated for Parkinson’s disease, is under phase II trial.
Furthermore, the government is undertaking various initiatives to provide better facilities, such as reimbursement for neurological diagnostic tests, which is likely to drive the market. Many healthcare institutions are working with laboratories to integrate different tests. High awareness about blood-based biomarker tests, a rise in the demand for affordable services, and technological advancements are some of the key factors expected to boost the market growth.
On the other hand, technological advancements are leading to an increase in the adoption of molecular diagnostics. Molecular diagnostics are based on the detection and amplification of nucleic acids, and these tests are more sensitive & provide specific results. As a result, the introduction of various quantitative and qualitative molecular assays, such as real-time PCR, LAMP-PCR, multiplex PCR, & digital PCR, that are capable of detecting low levels of analytes are expected to limit the demand of immunoassays for neurological biomarkers during the forecast period.
Biomarkers play a crucial role in selecting appropriate therapies and tracking disease progression. This can be evidenced by research initiatives and clinical studies that are being conducted in hospitals for developing biomarker tests, which, in turn, is anticipated to fuel market growth. For instance, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau is studying circulating microparticles to develop new biomarkers for neurological prognosis of patients.
Moreover, advancements in technologies help in the identification of early signs related to neurological disorders by detecting biomarkers in serum and blood. Some of the multiplexed immunoassay technologies include Olink's Proximity Extension Assay (PEA) and Quanterix's Simoa. Simoa is based on digitizing ELISA, which allows quantifying biomarkers in both blood and CSF, whereas PEA is based on nucleic acid technologies, helps prevent antibody cross-reactivity with immunoassay.
The rising number of disease-modifying therapies for neurological disorders is boosting the demand for immunoassays for biomarker testing in the market. For instance, in June 2021, the FDA granted accelerated approval to Aduhelm indicated for Alzheimer’s disease. Similarly, in January 2023, the FDA approved Alzheimer’s drug Leqembi (lecanemab). In addition, there are a number of disease-modifying therapies under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative growth opportunities for market players. For instance, as of November 2022, Roche’s RO7046015, indicated for Parkinson’s disease, is under phase II trial.
Furthermore, the government is undertaking various initiatives to provide better facilities, such as reimbursement for neurological diagnostic tests, which is likely to drive the market. Many healthcare institutions are working with laboratories to integrate different tests. High awareness about blood-based biomarker tests, a rise in the demand for affordable services, and technological advancements are some of the key factors expected to boost the market growth.
On the other hand, technological advancements are leading to an increase in the adoption of molecular diagnostics. Molecular diagnostics are based on the detection and amplification of nucleic acids, and these tests are more sensitive & provide specific results. As a result, the introduction of various quantitative and qualitative molecular assays, such as real-time PCR, LAMP-PCR, multiplex PCR, & digital PCR, that are capable of detecting low levels of analytes are expected to limit the demand of immunoassays for neurological biomarkers during the forecast period.
Immunoassay for Neurological Biomarkers Market Report Highlights
- Reagents segment held the largest share of 66.78% in 2022. This can be attributed to the increasing demand of immunoassay reagents for the diagnosis of neurological conditions and the growing disease burden
- By disease, the Alzheimer’s disease segment accounted for the largest share of 38.04% in 2022. The large share is due to the higher number of approved biomarkers, rise in prevalence of Alzheimer’s disease globally, and growing funding for the biomarker discovery
- By application, research application segment dominated the market in 2022 with a share of 68.17%, owing to the increasing applications of immunoassays in neurological R&D for biomarker discovery, validation, and qualification of various neurological disorders
- North America held the largest market share of 48.81% in 2022. The large share can be attributed to established healthcare infrastructure, increased per capita healthcare expenditure, in addition to rising funding and investments for neurological biomarker research in the region
Table of Contents
Chapter 1 Methodology And Scope1.1 Market Segmentation And Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
Chapter 3 Immunoassays For Neurological Biomarkers Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)
3.1 Definition and Scope
3.2 Product Market Share Analysis, 2022 & 2030
3.3 Segment Dashboard
3.4 Global Immunoassays for Neurological Biomarkers Market, by Product, 2018 to 2030
3.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
3.5.1 Instruments
3.5.1.1 Instruments Market, 2018 - 2030 (USD Million)
3.5.2 Reagents
3.5.2.1 Reagents Market, 2018 - 2030 (USD Million)
3.5.3 Services
3.5.3.1 Services Market, 2018 - 2030 (USD Million)
Chapter 4 Immunoassays for Neurological Biomarkers Market: Segment Analysis, by Disease, 2018 - 2030 (USD Million)
4.1 Definition and Scope
4.2 Disease Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global Immunoassays for Neurological Biomarkers Market, by Disease, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Alzheimer’s Disease
4.5.1.1 Alzheimer’s Disease Market, 2018 - 2030 (USD Million)
4.5.2 Parkinson’s Disease
4.5.2.1 Parkinson’s Disease Market, 2018 - 2030 (USD Million)
4.5.3 Multiple Sclerosis
4.5.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
4.5.4 Others
4.5.4.1 Others Market, 2018 - 2030 (USD Million)
Chapter 5 Immunoassays For Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)
5.1 Definition And Scope
5.2 Application Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 Immunoassays For Neurological Biomarkers Market, By Application, 2018 To 2030
5.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
5.5.1 In Vitro Diagnostics Application
5.5.1.1 In Vitro Diagnostics Application Market, 2018 - 2030 (USD Million)
5.5.2 Research Application
5.5.2.1 Research Application Market, 2018 - 2030 (USD Million)
Chapter 6 Immunoassays For Neurological Biomarkers Market: Regional Estimates And Trend Analysis, By Product, Disease, & Application
6.1 North America
6.1.1 Swot Analysis
6.1.1.1 North America Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.1.2 U.S.
6.1.2.1 Key Country Dynamics
6.1.2.2 Target Disease Prevalence
6.1.2.3 Competitive Scenario
6.1.2.4 Regulatory Framework
6.1.2.5 Reimbursement Scenario
6.1.2.6 U.S. Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.1.3 Canada
6.1.3.1 Key Country Dynamics
6.1.3.2 Target Disease Prevalence
6.1.3.3 Competitive Scenario
6.1.3.4 Regulatory Framework
6.1.3.5 Reimbursement Scenario
6.1.3.6 Canada Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2 Europe
6.2.1 Swot Analysis
6.2.1.1 Europe Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.2 Germany
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 Competitive Scenario
6.2.2.4 Regulatory Framework
6.2.2.5 Reimbursement Scenario
6.2.2.6 Germany Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.3 U.K.
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Competitive Scenario
6.2.3.4 Regulatory Framework
6.2.3.5 Reimbursement Scenario
6.2.3.6 U.K. Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.4 France
6.2.4.1 Key Country Dynamics
6.2.4.2 Target Disease Prevalence
6.2.4.3 Competitive Scenario
6.2.4.4 Regulatory Framework
6.2.4.5 Reimbursement Scenario
6.2.4.6 France Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.5 Italy
6.2.5.1 Key Country Dynamics
6.2.5.2 Target Disease Prevalence
6.2.5.3 Competitive Scenario
6.2.5.4 Regulatory Framework
6.2.5.5 Reimbursement Scenario
6.2.5.6 Italy Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.6 Spain
6.2.6.1 Key Country Dynamics
6.2.6.2 Target Disease Prevalence
6.2.6.3 Competitive Scenario
6.2.6.4 Regulatory Framework
6.2.6.5 Reimbursement Scenario
6.2.6.6 Spain Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.7 Denmark
6.2.7.1 Key Country Dynamics
6.2.7.2 Target Disease Prevalence
6.2.7.3 Competitive Scenario
6.2.7.4 Regulatory Framework
6.2.7.5 Reimbursement Scenario
6.2.7.6 Denmark Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.8 Sweden
6.2.8.1 Key Country Dynamics
6.2.8.2 Target Disease Prevalence
6.2.8.3 Competitive Scenario
6.2.8.4 Regulatory Framework
6.2.8.5 Reimbursement Scenario
6.2.8.6 Sweden Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.9 Norway
6.2.9.1 Key Country Dynamics
6.2.9.2 Target Disease Prevalence
6.2.9.3 Competitive Scenario
6.2.9.4 Regulatory Framework
6.2.9.5 Reimbursement Scenario
6.2.9.6 Norway Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.10 Rest Of Europe Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3 Asia Pacific
6.3.1 Swot Analysis
6.3.1.1 Asia Pacific Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2 Japan
6.3.2.1 Key Country Dynamics
6.3.2.2 Target Disease Prevalence
6.3.2.3 Competitive Scenario
6.3.2.4 Regulatory Framework
6.3.2.5 Reimbursement Scenario
6.3.2.6 Japan Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3 China
6.3.3.1 Key Country Dynamics
6.3.3.2 Target Disease Prevalence
6.3.3.3 Competitive Scenario
6.3.3.4 Regulatory Framework
6.3.3.5 Reimbursement Scenario
6.3.3.6 China Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.4 India
6.3.4.1 Key Country Dynamics
6.3.4.2 Target Disease Prevalence
6.3.4.3 Competitive Scenario
6.3.4.4 Regulatory Framework
6.3.4.5 Reimbursement Scenario
6.3.4.6 India Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.5 South Korea
6.3.5.1 Key Country Dynamics
6.3.5.2 Target Disease Prevalence
6.3.5.3 Competitive Scenario
6.3.5.4 Regulatory Framework
6.3.5.5 Reimbursement Scenario
6.3.5.6 South Korea Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.6 Australia
6.3.6.1 Key Country Dynamics
6.3.6.2 Target Disease Prevalence
6.3.6.3 Competitive Scenario
6.3.6.4 Regulatory Framework
6.3.6.5 Reimbursement Scenario
6.3.6.6 Australia Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.7 Thailand
6.3.7.1 Key Country Dynamics
6.3.7.2 Target Disease Prevalence
6.3.7.3 Competitive Scenario
6.3.7.4 Regulatory Framework
6.3.7.5 Reimbursement Scenario
6.3.7.6 Thailand Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.8 Rest Of Asia Pacific Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4 Latin America
6.4.1 Swot Analysis
6.4.1.1 Latin America Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2 Brazil
6.4.2.1 Key Country Dynamics
6.4.2.2 Target Disease Prevalence
6.4.2.3 Competitive Scenario
6.4.2.4 Regulatory Framework
6.4.2.5 Reimbursement Scenario
6.4.2.6 Brazil Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.3 Mexico
6.4.3.1 Key Country Dynamics
6.4.3.2 Target Disease Prevalence
6.4.3.3 Competitive Scenario
6.4.3.4 Regulatory Framework
6.4.3.5 Reimbursement Scenario
6.4.3.6 Mexico Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.4 Argentina
6.4.4.1 Key Country Dynamics
6.4.4.2 Target Disease Prevalence
6.4.4.3 Competitive Scenario
6.4.4.4 Regulatory Framework
6.4.4.5 Reimbursement Scenario
6.4.4.6 Argentina Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.5 Rest Of Latam Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5 Middle East & Africa (MEA)
6.5.1 Swot Analysis
6.5.1.1 Middle East & Africa Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.2 South Africa
6.5.2.1 Key Country Dynamics
6.5.2.2 Target Disease Prevalence
6.5.2.3 Competitive Scenario
6.5.2.4 Regulatory Framework
6.5.2.5 Reimbursement Scenario
6.5.2.6 South Africa Immunoassay For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.3 Saudi Arabia
6.5.3.1 Key Country Dynamics
6.5.3.2 Target Disease Prevalence
6.5.3.3 Competitive Scenario
6.5.3.4 Regulatory Framework
6.5.3.5 Reimbursement Scenario
6.5.3.6 Saudi Arabia Immunoassay For Neurological Biomarkers
6.5.3.7 Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.4 UAE
6.5.4.1 Key Country Dynamics
6.5.4.2 Target Disease Prevalence
6.5.4.3 Competitive Scenario
6.5.4.4 Regulatory Framework
6.5.4.5 Reimbursement Scenario
6.5.4.6 Uae Immunoassay For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.5 Kuwait
6.5.5.1 Key Country Dynamics
6.5.5.2 Target Disease Prevalence
6.5.5.3 Competitive Scenario
6.5.5.4 Regulatory Framework
6.5.5.5 Reimbursement Scenario
6.5.5.6 Kuwait Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5.6 Rest Of MEA Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Immunoassays For Neurological Biomarkers Market: Competitive Landscape
7.1 QIAGEN
7.2 Abbott
7.3 Merck & Co., Inc.
7.4 Johnson & Johnson Services, Inc.
7.5 Thermo Fisher Scientific, Inc.
7.6 Bio-Rad Laboratories, Inc.
7.7 Sysmex Corporation
7.8 Merck KGaA
7.9 F. Hoffmann La-Roche Ltd.
7.10 Nimble Therapeutics
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 4 Global immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 5 Global immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 6 Global immunoassays for neurological biomarkers market, by region, 2018 - 2030 (USD Million)
Table 7 North America immunoassays for neurological biomarkers market, by country, 2018 - 2030 (USD Million)
Table 8 North America immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 9 North America immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 10 North America immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 11 U.S. immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 12 U.S. immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 13 U.S. immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 14 Canada immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 15 Canada immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 16 Canada immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 17 Europe immunoassays for neurological biomarkers market, by country, 2018 - 2030 (USD Million)
Table 18 Europe immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 19 Europe immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 20 Europe immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 21 U.K. immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 22 U.K. immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 23 U.K. immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 24 Germany immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 25 Germany immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 26 Germany immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 27 France immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 28 France immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 29 France immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 30 Italy immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 31 Italy immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 32 Italy immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 33 Spain immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 34 Spain immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 35 Spain immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 36 Denmark immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 37 Denmark immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 38 Denmark immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 39 Sweden immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 40 Sweden immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 41 Sweden immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 42 Norway immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 43 Norway immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 44 Norway immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 45 Asia Pacific immunoassays for neurological biomarkers market, by country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 47 Asia Pacific immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 48 Asia Pacific immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 49 Japan immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 50 Japan immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 51 Japan immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 52 China immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 53 China immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 54 China immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 55 India immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 56 India immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 57 India immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 58 Australia immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 59 Australia immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 60 Australia immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 61 Thailand immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 62 Thailand immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 63 Thailand immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 64 South Korea immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 65 South Korea immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 66 South Korea immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 67 Latin America immunoassays for neurological biomarkers market, by country, 2018 - 2030 (USD Million)
Table 68 Latin America immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 69 Latin America immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 70 Latin America immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 71 Brazil immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 72 Brazil immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 73 Brazil immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 74 Mexico immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 75 Mexico immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 76 Mexico immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 77 Argentina immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 78 Argentina immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 79 Argentina immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa immunoassays for neurological biomarkers market, by country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 84 South Africa immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 85 South Africa immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 86 South Africa immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 90 UAE immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 91 UAE immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 92 UAE immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 93 Kuwait immunoassays for neurological biomarkers market, by product, 2018 - 2030 (USD Million)
Table 94 Kuwait immunoassays for neurological biomarkers market, by disease, 2018 - 2030 (USD Million)
Table 95 Kuwait immunoassays for neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 96 Participant’s overview
Table 97 Financial performance
Table 98 Key companies undergoing expansions.
Table 99 Key companies undergoing acquisitions.
Table 100 Key companies undergoing collaborations.
Table 101 Key companies launching new products/services.
Table 102 Key companies undergoing partnerships.
Table 103 Key companies undertaking other strategies.
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market summary, 2022 (USD Million)
Fig. 9 Market segmentation & scope
Fig. 10 Market driver impact
Fig. 11 Market restraint impact
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s analysis
Fig. 14 SWOT analysis
Fig. 15 Immunoassays for neurological biomarkers market: Product outlook and key takeaways
Fig. 16 Immunoassays for neurological biomarkers market: Product movement analysis
Fig. 17 Global instruments market, 2018 - 2030 (USD Million)
Fig. 18 Global reagents market, 2018 - 2030 (USD Million)
Fig. 19 Global services market, 2018 - 2030 (USD Million)
Fig. 20 Immunoassays for neurological biomarkers market: Disease outlook and key takeaways
Fig. 21 Immunoassays for neurological biomarkers market: Disease movement analysis
Fig. 22 Global Alzheimer’s disease market, 2018 - 2030 (USD Million)
Fig. 23 Global Parkinson’s disease market, 2018 - 2030 (USD Million)
Fig. 24 Global multiple sclerosis market, 2018 - 2030 (USD Million)
Fig. 25 Global others market, 2018 - 2030 (USD Million)
Fig. 26 Immunoassays for neurological biomarkers market: Application outlook and key takeaways
Fig. 27 Immunoassays for neurological biomarkers market: Application movement analysis
Fig. 28 Global in vitro diagnostics application market, 2018 - 2030 (USD Million)
Fig. 29 Global research application market, 2018 - 2030 (USD Million)
Fig. 30 Immunoassays for neurological biomarkers market: Regional outlook and key takeaways
Fig. 31 North America: SWOT Analysis
Fig. 32 North America immunoassays for neurological biomarkers market, 2018 - 2030 (USD Million)
Fig. 33 U.S. key country dynamics
Fig. 34 U.S. immunoassays for neurological biomarkers market, 2018 - 2030 (USD Million)
Fig. 35 Canada key country dynamics
Fig. 36 Canada immunoassays for neurological biomarkers market, 2018 - 2030 (USD Million)
Fig. 37 Europe: SWOT Analysis
Fig. 38 Europe immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 U.K. key country dynamics
Fig. 40 U.K. immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany key country dynamics
Fig. 42 Germany immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 France key country dynamics
Fig. 44 France immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Italy key country dynamics
Fig. 46 Italy immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Spain key country dynamics
Fig. 48 Spain immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Denmark key country dynamics
Fig. 50 Denmark immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Sweden key country dynamics
Fig. 52 Sweden immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Norway key country dynamics
Fig. 54 Norway immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Asia-Pacific: SWOT Analysis
Fig. 56 Asia-Pacific immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Japan key country dynamics
Fig. 58 Japan immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 China key country dynamics
Fig. 60 China immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 India key country dynamics
Fig. 62 India immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Australia key country dynamics
Fig. 64 Australia immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Thailand key country dynamics
Fig. 66 Thailand immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 South Korea key country dynamics
Fig. 68 South Korea immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Latin America: SWOT Analysis
Fig. 70 Latin America immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Brazil key country dynamics
Fig. 72 Brazil immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Mexico key country dynamics
Fig. 74 Mexico immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Argentina key country dynamics
Fig. 76 Argentina immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 MEA: SWOT Analysis
Fig. 78 MEA immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 South Africa key country dynamics
Fig. 80 South Africa immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Saudi Arabia key country dynamics
Fig. 82 Saudi Arabia immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 UAE key country dynamics
Fig. 84 UAE immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Kuwait key country dynamics
Fig. 86 Kuwait immunoassays for neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Market participant categorization
Fig. 88 Immunoassays for neurological biomarkers market share analysis, 2022
Fig. 89 Strategy framework
Companies Mentioned
- QIAGEN
- Abbott
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Merck KGaA
- F. Hoffmann La-Roche Ltd.
- Nimble Therapeutics
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 134 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 601.52 Million |
| Forecasted Market Value ( USD | $ 2240 Million |
| Compound Annual Growth Rate | 17.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
